Montelukast Ametas (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells and inflammatory cells. This inhibition prevents leukotriene D4 from causing bronchoconstriction, mucus secretion, and vascular leakage, thereby reducing airway narrowing and inflammation associated with asthma and allergic reactions.

The appropriate dose of Montelukast Ametas is determined by the prescribing healthcare professional based on the patient’s age, weight, and specific condition. Dosage forms and strengths may vary, and the prescriber will provide individualized instructions that should be followed exactly as written.

Safety data for Montelukast in pregnancy and lactation are limited. The drug is classified as pregnancy category ? (unknown), and clinicians usually weigh potential benefits against possible risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider before starting therapy.

To order Montelukast Ametas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and the necessary import documentation.

Montelukast is often compared with inhaled corticosteroids (ICS) for asthma control. While ICS directly reduce airway inflammation, Montelukast targets leukotriene‑mediated pathways and is taken orally, making it useful as an add‑on therapy or for patients who cannot tolerate inhalers. For allergic rhinitis, antihistamines are another option; Montelukast may provide additional benefit for patients with concurrent asthma.

Montelukast Ametas should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources. If tablets become damaged or discolored, discard them and obtain a new supply.

Montelukast Ametas is administered orally, usually as a single tablet taken once daily in the evening. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional. Consistent timing helps maintain steady drug levels and maximizes therapeutic effect.

The most serious risks associated with Montelukast include rare but severe neuropsychiatric events such as depression, suicidal thoughts, or mood swings, as well as allergic reactions that may cause rash, angioedema, or anaphylaxis. Liver function abnormalities have also been reported. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast should not be used in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised in patients with uncontrolled asthma, as it is not a rescue medication. Pregnant or nursing women, and patients with severe hepatic impairment, should only use Montelukast after a thorough risk‑benefit assessment by their physician.